Supriya Lifescience Limited

NSEI:SUPRIYA Stock Report

Market Cap: ₹30.8b

Supriya Lifescience Valuation

Is SUPRIYA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUPRIYA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUPRIYA (₹384.45) is trading above our estimate of fair value (₹12.8)

Significantly Below Fair Value: SUPRIYA is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUPRIYA?

Other financial metrics that can be useful for relative valuation.

SUPRIYA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA17.4x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does SUPRIYA's PE Ratio compare to its peers?

The above table shows the PE ratio for SUPRIYA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.7x
509079 Gufic Biosciences
38.7xn/a₹33.3b
INDOCO Indoco Remedies
38.7x43.0%₹29.4b
500288 Morepen Laboratories
29.1xn/a₹28.0b
RPGLIFE RPG Life Sciences
36.3xn/a₹31.4b
SUPRIYA Supriya Lifescience
26x20.3%₹30.8b

Price-To-Earnings vs Peers: SUPRIYA is good value based on its Price-To-Earnings Ratio (26x) compared to the peer average (35.7x).


Price to Earnings Ratio vs Industry

How does SUPRIYA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SUPRIYA is good value based on its Price-To-Earnings Ratio (26x) compared to the Indian Pharmaceuticals industry average (34.5x).


Price to Earnings Ratio vs Fair Ratio

What is SUPRIYA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUPRIYA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26x
Fair PE Ratio29.4x

Price-To-Earnings vs Fair Ratio: SUPRIYA is good value based on its Price-To-Earnings Ratio (26x) compared to the estimated Fair Price-To-Earnings Ratio (29.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.